How should I manage a multiple myeloma patient receiving bortezomib (Velcade) and daratumumab (Darzalex) who has a uric acid of 14.2 mg/dL and a hemoglobin of 5.8 g/dL?

Immediate Life-Threatening Emergency Management

This patient requires immediate hospitalization for severe tumor lysis syndrome (TLS) with critical anemia—hold all myeloma therapy immediately, initiate aggressive IV hydration, start rasburicase for hyperuricemia, and transfuse packed red blood cells urgently to hemoglobin >7 g/dL.

Critical Laboratory Abnormalities

Your patient presents with two life-threatening complications:

• Uric acid 14.2 mg/dL: Severe hyperuricemia indicating acute tumor lysis syndrome (TLS), likely precipitated by the myeloma therapy
• Hemoglobin 5.8 g/dL: Severe anemia requiring immediate transfusion support

Immediate Management Algorithm

Step 1: Hold All Myeloma Therapy

• Stop Velcade (bortezomib) and Darzalex (daratumumab) immediately until metabolic derangements are corrected
• Both agents can be safely restarted once TLS resolves, as bortezomib requires no dose adjustment for renal impairment 1

Step 2: Manage Tumor Lysis Syndrome

Hyperuricemia Management:

• Rasburicase 0.2 mg/kg IV as single dose (preferred over allopurinol for uric acid >10 mg/dL) 1
• Aggressive IV hydration: 150-200 mL/hour normal saline targeting urine output 100-150 mL/hour 1
• Avoid alkalinization of urine (outdated practice that can worsen calcium phosphate precipitation)
• Monitor uric acid, potassium, phosphorus, calcium, and creatinine every 6-8 hours

Critical Monitoring:

• Check complete metabolic panel immediately for potassium, phosphorus, calcium, and creatinine
• Assess for acute kidney injury (common with cast nephropathy in myeloma + TLS)
• Obtain ECG to evaluate for hyperkalemia-related changes

Step 3: Manage Severe Anemia

Transfusion Strategy:

• Transfuse 2 units packed RBCs immediately, targeting hemoglobin >7 g/dL initially
• Consider higher target (8-9 g/dL) if patient symptomatic or has cardiac comorbidities
• Grade 3-4 anemia occurs in 3-19% of patients on novel myeloma agents 2

Evaluate Anemia Etiology:

• Obtain reticulocyte count, LDH, haptoglobin, direct antiglobulin test (DAT)
• Important caveat: Daratumumab causes positive DAT in >90% of patients, which can interfere with blood bank testing 3—ensure blood bank is aware patient is on daratumumab
• Check iron studies, B12, folate
• Review bone marrow involvement from myeloma

Step 4: Assess Renal Function

Renal Workup:

• Calculate eGFR and obtain 24-hour urine for protein quantification 1
• Serum free light chains to assess for cast nephropathy
• If creatinine elevated without clear explanation, consider renal biopsy to rule out light chain cast nephropathy, amyloidosis, or monoclonal immunoglobulin deposition disease 1

Key Advantage of Current Regimen:

• Bortezomib requires no dose adjustment for renal impairment and can be continued even in dialysis patients 1
• Daratumumab also does not require renal dose adjustment 3
• This makes your current regimen ideal once metabolic crisis resolves

Supportive Care During Crisis

Infection Prophylaxis:

• Neutropenia is common with daratumumab combinations 2
• Consider G-CSF if neutropenic (ANC <1000)
• Maintain herpes zoster prophylaxis with acyclovir/valacyclovir during bortezomib therapy 4

Thrombocytopenia Management:

• Check platelet count—thrombocytopenia occurs in 45% with daratumumab/bortezomib combinations 5
• Hold therapy if platelets <25,000 or active bleeding

Resuming Myeloma Therapy

Restart Criteria:

• Uric acid <7-8 mg/dL
• Hemoglobin >7 g/dL (ideally >8 g/dL)
• Potassium, phosphorus, calcium normalized
• Adequate urine output maintained

Dose Modifications Upon Restart:

• Bortezomib: Can resume at full dose 1.3 mg/m² as no renal adjustment needed 1
• Daratumumab: Resume at standard 16 mg/kg dosing 3
• Consider reducing bortezomib frequency to weekly (instead of twice weekly) if patient had significant toxicity 4

Common Pitfalls to Avoid

1. Do not continue myeloma therapy during active TLS—this will worsen metabolic derangements
2. Do not use allopurinol alone for uric acid >10 mg/dL—rasburicase is superior for rapid reduction
3. Do not transfuse without notifying blood bank of daratumumab use—causes false-positive antibody screens
4. Do not assume anemia is purely myeloma-related—evaluate for hemolysis, bleeding, nutritional deficiencies
5. Do not delay nephrology consultation if creatinine rising—early intervention improves renal recovery 1

Evidence Quality Note

The management approach prioritizes guideline recommendations from NCCN 2020 1 and ASCO/CCO 2019 2 for supportive care in myeloma, combined with FDA labeling for daratumumab 3. The combination of bortezomib and daratumumab is strongly supported by phase 3 data showing superior progression-free survival 5, but patient safety with metabolic stabilization must take absolute priority over disease control in this acute setting.